One year of adjuvant trastuzumab emtansine (T-DM1) leads to an impressive 5-year invasive disease-free survival rate of 97% among women with stage I human epidermal growth factor receptor 2 ...
Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive ...
Findings from the phase III HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium showed that the addition of tucatinib (Tukysa) to trastuzumab emtansine (T-DM1, Kadcyla) extended ...
More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...
ZURICH, March 30 (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a ...
SAN ANTONIO — The antibody-drug conjugate trastuzumab emtansine (T-DM1) does not improve survival outcomes compared with the standard of care in older patients with advanced human epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results